What’s new? Breast cancers that overexpress HER2 tend to spread to the central nervous system (CNS). While this phenomenon can be influenced by targeted therapy, HER2‐positive tumors may be biologica…
In this episode of The Live Today podcast we interview Dr. Lewis, Brinlee’s oncologist, who shares his incredible journey from losing his father to cancer…
Products that are inspired by a perspective change that came from a cancer diagnosis. Join our community of hope.
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
In the article that accompanies this editorial, Lorenzen et al 1 report exploratory efficacy findings, focused on pathologic response, of neoadjuvant immunotherapy–containing chemotherapy in patients…
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
We read the CALGB (Cancer and Leukemia Group B) 80403 study results with interest. 1 This randomized three-arm trial added cetuximab to each of three…
In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical…
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and…
With approval from its Board of Trustees, Brigham Young University has appointed Dr. Mark Ott as the inaugural dean of BYU’s medical school.
